Frank Yocca - 20 Jan 2023 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Role
Chief Scientific Officer
Signature
/s/ Richard I. Steinhart, as Attorney-in-Fact for Frank Yocca
Issuer symbol
BTAI
Transactions as of
20 Jan 2023
Net transactions value
-$1,500,000
Form type
4
Filing time
24 Jan 2023, 19:08:20 UTC
Previous filing
16 Mar 2022
Next filing
16 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BTAI Common Stock Sale $1,500,000 -50,000 -86% $30.00 8,397 20 Jan 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1.
F2 The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $30.00 to $30.03. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.